Dual Immune Regulatory Roles of Interleukin-33 in Pathological Conditions

Cells. 2022 Oct 14;11(20):3237. doi: 10.3390/cells11203237.

Abstract

Interleukin-33 (IL-33), a member of the IL-1 cytokine family and a multifunctional cytokine, plays critical roles in maintaining host homeostasis and in pathological conditions, such as allergy, infectious diseases, and cancer, by acting on multiple types of immune cells and promoting type 1 and 2 immune responses. IL-33 is rapidly released by immune and non-immune cells upon stimulation by stress, acting as an "alarmin" by binding to its receptor, suppression of tumorigenicity 2 (ST2), to trigger downstream signaling pathways and activate inflammatory and immune responses. It has been recognized that IL-33 displays dual-functioning immune regulatory effects in many diseases and has both pro- and anti-tumorigenic effects, likely depending on its primary target cells, IL-33/sST2 expression levels, cellular context, and the cytokine microenvironment. Herein, we summarize our current understanding of the biological functions of IL-33 and its roles in the pathogenesis of various conditions, including inflammatory and autoimmune diseases, infections, cancers, and cases of organ transplantation. We emphasize the nature of context-dependent dual immune regulatory functions of IL-33 in many cells and diseases and review systemic studies to understand the distinct roles of IL-33 in different cells, which is essential to the development of more effective diagnoses and therapeutic approaches for IL-33-related diseases.

Keywords: IL-33; ST2; alarmin; disease; immune system; inflammation; organ transplantation.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoimmune Diseases* / immunology
  • Humans
  • Infections* / immunology
  • Inflammation* / immunology
  • Interleukin-1 Receptor-Like 1 Protein / metabolism
  • Interleukin-1* / metabolism
  • Interleukin-33* / metabolism
  • Neoplasms* / immunology
  • Organ Transplantation
  • Tumor Microenvironment

Substances

  • Interleukin-1
  • Interleukin-1 Receptor-Like 1 Protein
  • Interleukin-33

Grants and funding

This work was supported by grants from the National Natural Science Foundation (31930041, Y.Z.), the National Key Research and Development Program of China (2017YFA0105002, 2017YFA0104402, Y.Z.), and the Knowledge Innovation Program of the Chinese Academy of Sciences (XDA16030301, Y.Z.).